Linsalata Michele, Russo Francesco, Berloco Pasquale, Caruso Maria Lucia, Matteo Giovanni D I, Cifone Maria Grazia, Simone Claudio D E, Ierardi Enzo, Di Leo Alfredo
Laboratory of Biochemistry, Scientific Institute for Digestive Diseases IRCCS 'Saverio de Bellis', Bari, Italy.
Helicobacter. 2004 Apr;9(2):165-72. doi: 10.1111/j.1083-4389.2004.00214.x.
Functional probiotics may prevent Helicobacter pylori infection, and some evidence suggests that they also possess antitumor properties. Lactobacillus brevis (CD2) is a functional Lactobacillus strain with peculiar biochemical features, essentially related to the activity of arginine deiminase. This enzyme catalyzes the catabolism of arginine and affects the biosynthesis of polyamines (putrescine, spermidine, and spermine). Polyamines are polycations found in high concentrations in both normal and neoplastic cells. Our aims were: 1, to assess whether oral administration of L. brevis (CD2) affects H. pylori survival in the human gastric mucosa; 2, to evaluate the effects of L. brevis (CD2) on polyamine biosynthesis in gastric biopsies from H. pylori-positive patients.
For 3 weeks before endoscopy, 22 H. pylori-positive dyspeptic patients randomly received (ratio 1 : 1) high oral doses of L. brevis (CD2) or placebo. Before and after treatment, H. pylori infection was determined by urea breath test (UBT). In gastric biopsies, ornithine decarboxylase activity and polyamine levels were, respectively, evaluated by a radiometric technique and high-pressure liquid chromatography (HPLC).
L. brevis (CD2) treatment did not eradicate H. pylori. However, a reduction in the UBT delta values occurred, suggesting a decrease in intragastric bacterial load. Significantly, L. brevis (CD2) induced a decrease in gastric ornithine decarboxylase activity and polyamine levels.
Our data support the hypothesis that L. brevis (CD2) treatment decreases H. pylori colonization, thus reducing polyamine biosynthesis. Alternatively, the arginine deiminase activity following L. brevis (CD2) administration might cause arginine deficiency, preventing polyamine generation from gastric cells.
功能性益生菌可能预防幽门螺杆菌感染，并且一些证据表明它们还具有抗肿瘤特性。短乳杆菌（CD2）是一种具有独特生化特性的功能性乳杆菌菌株，主要与精氨酸脱亚氨酶的活性有关。该酶催化精氨酸的分解代谢，并影响多胺（腐胺、亚精胺和精胺）的生物合成。多胺是在正常细胞和肿瘤细胞中均以高浓度存在的聚阳离子。我们的目的是：1.评估口服短乳杆菌（CD2）是否会影响人胃黏膜中幽门螺杆菌的存活；2.评估短乳杆菌（CD2）对幽门螺杆菌阳性患者胃活检组织中多胺生物合成的影响。
在内镜检查前3周，22名幽门螺杆菌阳性的消化不良患者随机接受（比例为1:1）高剂量口服短乳杆菌（CD2）或安慰剂。治疗前后，通过尿素呼气试验（UBT）确定幽门螺杆菌感染情况。在胃活检组织中，分别通过放射测量技术和高压液相色谱法（HPLC）评估鸟氨酸脱羧酶活性和多胺水平。
短乳杆菌（CD2）治疗未根除幽门螺杆菌。然而，UBT差值出现降低，提示胃内细菌载量减少。值得注意的是，短乳杆菌（CD2）导致胃鸟氨酸脱羧酶活性和多胺水平降低。
我们的数据支持以下假设，即短乳杆菌（CD2）治疗可减少幽门螺杆菌定植，从而减少多胺生物合成。或者，口服短乳杆菌（CD2）后精氨酸脱亚氨酶活性可能导致精氨酸缺乏，从而阻止胃细胞产生多胺。
